Completed PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT04172233

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

A Randomized, Double-blinded, and Placebo-controlled Phase I/II Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Sponsor: Akeso

Conditions Plaque Psoriasis

Interventions AK101 placebo

Updated 5 times since 2019 Last updated: Feb 27, 2025 Started: Jan 9, 2018 Primary completion: Oct 31, 2019 Completion: Oct 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Plaque Psoriasis, this trial is completed. The trial is conducted by Akeso and has accumulated 5 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Apr 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akeso
Akeso Tiancheng, Inc

Data source: Akeso

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China